Prostate Cancer Daily

May 15, 2026

Videos

Peer-to-Peer Clinical Conversations

Approaches to Early-Stage Development and Dose Optimization "Presentation" - Anna Karmann

Anna Karmann

At the 2026 UCSF-UCLA PSMA Conference, Anna Karmann argues that radiopharmaceutical dose optimization has been neglected in prostate cancer drug development.

View

PARP Inhibitors in Prostate Cancer: A Decade of Development and the Combination vs Monotherapy Debate for HRR-Mutated Disease - Neeraj Agarwal

Neeraj Agarwal

Pedro Barata interviews Neeraj Agarwal about PARP inhibitors in prostate cancer following an educational session.

View

Beyond the Abstracts

Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy - Beyond the Abstract

The Emerging Role of PARP Inhibitors in Prostate Cancer: A Narrative Review - Beyond the Abstract

Conference Coverage

APCCC 2026: What Role Does Quality of Life Play in This Setting?

APCCC 2026: rPFS as a Surrogate for Hard Endpoints in mHSPC: Evidence and Regulatory Implications

APCCC 2026: In mHSPC Trials, What Are Relevant Endpoints from a Clinical Point of View?

PSMA and Beyond 2026: PSMA PET in Prostate Cancer Drug Development: Regulatory Challenges and Considerations

SES AUA 2026: Darolutamide Plus Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume in the Phase 3 ARANOTE Study

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Response assessment in [177Lu]PSMA: where do we stand?

Anthropometric assessment of obesity in robotic-assisted laparoscopic prostatectomy: A systematic review.

Contrast-free MRI-first screening in young asymptomatic men: Prostate characteristics and cancer detection rates.

Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multi-Center Validation Study.

NeuroSAFE-guided robot-assisted radical prostatectomy versus standard RARP: systematic review and meta-analysis of comparative studies.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login